A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

Preclinical studies indicate autophagy inhibition with hydroxychloroquine (HCQ) can augment the efficacy of DNA-damaging therapy. The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy of HCQ in combination with radiation therapy (RT) and temozolomide (TMZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenfeld, Myrna R, Ye, Xiaobu, Supko, Jeffrey G, Desideri, Serena, Grossman, Stuart A, Brem, Steven, Mikkelson, Tom, Wang, Daniel, Chang, Yunyoung C, Hu, Janice, McAfee, Quentin, Fisher, Joy, Troxel, Andrea B, Piao, Shengfu, Heitjan, Daniel F, Tan, Kay-See, Pontiggia, Laura, O’Dwyer, Peter J, Davis, Lisa E, Amaravadi, Ravi K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203513/
https://www.ncbi.nlm.nih.gov/pubmed/24991840
http://dx.doi.org/10.4161/auto.28984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203513/
https://www.ncbi.nlm.nih.gov/pubmed/24991840
http://dx.doi.org/10.4161/auto.28984

Ejemplares similares